Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits

Teva Pharmaceutical and AbbVie’s Allergan are finally on the verge of putting thousands of opioid lawsuits to bed.

The companies this week locked in a combined $6.6 billion in settlements to resolve allegations that they helped fuel the U.S. opioid epidemic by overstating the painkillers’ benefits, downplaying the risk of addiction and failing to maintain controls to prevent opioid misuse.